CAR T-Cell Therapy gudaha Turkiga

SABABTOO AH-daawaynta T waa nooc cusub oo daawaynta kansarka ah oo isticmaala habka difaaca si loo cirib tiro unugyada kansarka. Halka daawaynta kale ay ku guuldareysteen, waxay mararka qaarkood awood u yeelatay inay bogsato bukaanada. Blog-gani wuxuu iftiimin doonaa dhammaan waxaad u baahan tahay inaad ka ogaato habkan. Akhri si aad wax badan uga ogaato!

Waa maxay daaweynta unugyada CAR-T?

Daaweynta noocaan ah waxay ku lug leedahay wax ka beddelka unugyada T-da ee bukaanka, nooca unugyada difaaca, ee shaybaarka si ay u xidhaan una dilaan unugyada kansarka. Tuubbadu waxay dhiigga ka soo qaadaa xididka cududda bukaanka oo gaynaysa aaladda apheresis (aan la muujin), kaas oo soo saara unugyada dhiigga cad, oo ay ku jiraan unugyada T, oo ku soo celisa dhiigga soo hadhay bukaanka. 

Unugyada T ayaa markaa si hidde ahaan wax looga beddelay shaybaarka si ay ugu jiraan hidda-wadaha loogu talagalay soo-qabeyaal gaar ah oo loo yaqaanno reseptor-ka antigen-ka (CAR). Unugyada CAR T waxay ku bataan shaybaadhka ka hor inta aan la gelin bukaanka tiro badan. Antigen-ka unugyada kansarka waxaa aqoonsan kara unugyada CAR T, ka dibna dila unugyada kansarka.

Waa maxay nidaamka daawaynta unug ee CAR-T?

Habka daawaynta CAR-T, oo qaadata dhowr toddobaad, waxay ku lug leedahay tillaabooyin badan:

Unugyada T waxaa laga soo saaraa dhiiggaaga iyadoo la isticmaalayo tuubo la geliyo xididka cududda. Tani waxay qaadataa dhowr saacadood.

Unugyada T waxaa loo qaadaa xarun ay ku maraan beddelka hidde-sidaha si ay u noqdaan unugyo CAR-T. Laba ilaa saddex toddobaad ayaa ku dhammaanaya tan.

Unugyada CAR-T ayaa dib loogu soo celinayaa dhiiggaaga iyadoo loo marayo dhibic. Tani waxay u baahan tahay dhowr saacadood.

Unugyada CAR-T waxay beegsadaan oo tirtiraan unugyada kansarka ee jirka oo dhan. Ka dib markaad hesho daawaynta CAR-T, si dhow ayaa laguula socon doonaa.

Waa maxay waxyeelada daawaynta unug ee CAR-T?

Calaamadaha sii deynta Cytokine, or CRS, is the typical CAR T-cell side effect. Another name for it is “cytokine storm.” It is experienced by roughly 70–90% of patients, but it only lasts for five to seven days. The majority of people compare it to having a bad flu infection, complete with a high fever, exhaustion, and bodily aches. 

Maalinta labaad ama saddexaad ee ku xigta faleebada ayaa caadi ahaan marka ay bilaabato. Waxay ku dhacdaa iyada oo ay ugu wacan tahay habka difaaca jirka oo ka falcelinaya unugyada T-yada ee fidinta iyo weerarka malignantiga.

CRES, oo u taagan CAR T-cell-related encephalopathy syndrome, waa saamaynta kale ee xun. Qiyaastii maalinta shanaad ee ka dib faleebada, badanaa way bilaabataa. Bukaanka waxaa laga yaabaa inay qabaan jahawareer iyo jahawareer, marmarka qaarkoodna waxaa laga yaabaa inay awoodi waayaan inay hadlaan dhowr maalmood. 

In kasta oo CRES dib loo rogi karo oo caadi ahaan socoto inta u dhaxaysa laba iyo afar maalmood, waxay culays ku noqon kartaa bukaannada iyo qoysaskooda. Dhammaan hawlaha neerfaha si tartiib tartiib ah ayey caadi ugu soo noqdaan bukaanka.

Noocee ah unugyada kansarka ayaa lagu daweyn karaa CAR-T Cell Therapy? 

Only patients with adult B-cell non-lymphoma Hodgkin’s or pediatric acute lymphoblastic leukemia who have already tried two unsuccessful conventional therapies can currently use CAR T-cell therapy products that have received FDA approval. However, CAR T-cell therapy is now being tested in clinical studies as a first or second-line treatment for adult lymphoma and pediatric Lymphoblastic lymphoblastic leukemia.

Waa maxay faa'iidooyinka daaweynta unugyada CAR-T?

Faa'iidada ugu weyni waa in daawaynta CAR T-cell ay u baahan tahay faleebo keliya oo badanaa waxay u baahan tahay laba toddobaad oo keliya daryeelka bukaan-jiifka. Bukaanka qaba qanjirada unugyada 'Hodgkin' iyo leukemia-ga carruurta ee hadda la helay, dhanka kale, caadi ahaan waxay u baahan yihiin kiimoterabi ugu yaraan lix bilood ama ka badan.

Faa'iidooyinka daaweynta CAR T-cell, oo runtii ah dawo nool, waxay sii jiri kartaa sanado badan. Haddi iyo marka ay soo noqodku dhacdo, unugyadu wali way awoodi doonaan inay aqoonsadaan oo ay beegsadaan unugyada kansarka sababtoo ah waxay ku noolaan karaan jidhka muddo dheer. 

Although the information is still developing, 42% of adult qanjiro patients who underwent CD19 CAR T-cell treatment were still in remission after 15 months. And after six months, two-thirds of patients with pediatric acute lymphoblastic leukemia were still in remission. Unfortunately, these patients had exceedingly aggressive tumors that weren’t successfully treated using traditional standards of care.

Bukaanno noocee ah ayaa noqon lahaa kuwa si wanaagsan u qaata daawaynta unugyada CAR-T?

Musharaxa ugu wanagsan ee daawaynta unugyada CAR T-cell wakhtigan waa ilmo yar oo qaba lymfoblastic leukemia ba'an ama qof weyn oo qaba lymphoma B-cell oo daran kaas oo horey u lahaa laba xariiq oo daaweyn aan waxtar lahayn. 

Ka hor dhamaadka 2017, ma jirin heer la aqbalay daryeelka bukaanka kuwaas oo horay u soo maray laba xariiq oo daawaynta ah iyada oo aan la kulmin cafis. Daawaynta kaliya ee FDA-ansixisay ee ilaa hadda la caddeeyey inay faa'iido weyn u leedahay bukaankan waa daawaynta CAR T-cell.

Waa maxay baaxadda daawaynta unugyada CAR-T ee Turkiga?

A pilot tijaabada caafimaadka (NCT04206943) designed to assess the safety and feasibility of ISIKOK-19 T-cell therapy in patients with relapsed and refractory CD19+ tumors was conducted and participating patients received ISIKOK-19 infusions between October 2019 and July 2021. Production data of the first 8 patients and the clinical outcome of 7 patients who received ISIKOK-19 cell infusion is presented in this study.

Natiijooyinka: Sagaal bukaan ayaa loo diiwaan geliyay tijaabada (ALL n=5 iyo NHL n=4) laakiin 7 bukaan oo kaliya ayaa heli kara daaweynta. Laba ka mid ah saddexdii bukaan oo dhan iyo saddex ka mid ah afartii bukaan ee NHL waxay heleen jawaab celin dhammaystiran/qayb ah (ORR 72%). Afar bukaan (57%) ayaa lahaa CAR-T suntan la xiriirta (CRS, CRES, iyo pancytopenia). Laba bukaan ayaa jawaab celin waayay waxayna qabeen cudur sii socda ka dib daawaynta CAR-T. Laba bukaan oo qaba qayb jawaab celin ah ayaa lahaa cudur horusocod ah intii lagu jiray
dabagal

Gunaanad: Wax-soo-saarka wax-soo-saarka iyo buuxinta shuruudaha xakamaynta tayada ayaa ahaa mid lagu qanco wax-soo-saarka tacliinta. Heerarka jawaabta iyo astaamaha sunta waa la aqbali karaa kooxdan buka ee aadka loo sii daweeyay/dib-u-diritaan. Unugyada ISIKOK-19 waxay u muuqdaan inay yihiin badbaado, dhaqaale, iyo ikhtiyaar daawaynta hufan ee CD19 burooyinka togan. Natiijooyinka daraasaddan waxay u baahan yihiin inay noqdaan
Waxaa taageeray tijaabada caafimaad ee hadda socota ee ISIKOK-19.

Gunaanad

Tani waxay ka dhigan tahay horumar la taaban karo oo laga sameeyay maaraynta leukemia iyo lymphoma B-cell. Intaa waxa dheer, waxa ay rajo gelinaysaa kuwa hore loo saadaaliyay in noloshooda ay ku jirto lix bilood oo keliya. Hadda oo aanu aqoonsannay hababka wax-iska-caabbinta oo aanu abuurnay farsamooyin badan oo lagula dagaallamo, mustaqbalka waxa uu u muuqdaa mid aad u rajo badan.

Faahfaahin dheeraad ah oo ku saabsan CAR-T Cell Therapy ee Turkiga, u gudub our website. La xidhiidh bixiyaashayada daryeelka caafimaadka ee khibradda sare leh halkan CancerFax si aad u hesho la tashi bilaash ah si aad uga shaqeyso qorshe daryeel ku habboon baahiyahaaga daryeelka caafimaadka!

Sawirka: Mid ka mid ah cisbitaalka Turkiga oo lagu sameeyay tijaabooyinka daaweynta unugyada CAR T.